Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation

February 28, 2018 updated by: Dr. Joanna Stefaniak, Medical University of Vienna

Changes of Macrophage Migration Inhibitory Factor and Thyroid Hormones During Liver Transplantation. Association With Graft Dysfunction

Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Study Overview

Status

Unknown

Conditions

Detailed Description

Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Vienna, Austria, 1090
        • Medical University Vienna

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients undergoing orthotopic liver transplantation

Description

Inclusion Criteria:

  • End stage liver disease, chronic liver failure, orthotopic liver transplantation

Exclusion Criteria:

  • Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Patients undergoing OLT
Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Macrophage Migration Inhibitory Factor in human serum, liver graft effluent and urine
Time Frame: 24 months
24 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acute kidney injury, outcome
Time Frame: 48 months
Acute kidney injury, outcome
48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Vienna

Investigators

  • Study Chair: Peter Faybik, Prof, Medical University Vienna, Department of Anesthesia, General Intensive Care and Pain Management

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2014

Primary Completion (Anticipated)

September 1, 2018

Study Completion (Anticipated)

August 1, 2019

Study Registration Dates

First Submitted

January 12, 2016

First Submitted That Met QC Criteria

February 24, 2016

First Posted (Estimate)

March 2, 2016

Study Record Updates

Last Update Posted (Actual)

March 1, 2018

Last Update Submitted That Met QC Criteria

February 28, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 1458/2014

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Evidence of Liver Transplantation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe